FDA approves oral solution for prevention of nausea in cancer patients

MADISON, Miss. Granisol, an oral solution used for the prevention of nausea and vomiting in cancer patients, has been approved by the Food and Drug Administration. The drug is manufactured by Hawthorne Pharmaceuticals.

Granisol Oral Solution (granicetron hydrochloride) is used in patients who undergo emetogenic cancer therapy, which causes them to feel nauseous. Granisol is only available by prescription and is slated to begin shipping immediately through all national drug wholesalers.

According to Chris Smith, vice president of sales, research from the National Cancer Institute shows that oral mucositis occurs in the majority of patients receiving radiation for head the head and neck, in 75 percent who have to undergo bone marrow transplant and 40 percent of patients that receive chemotherapy. Based on those statistics, he states, “We feel this product will fill an important need in helping to prevent nausea and vomiting associated with chemotherapy or radiation for cancer therapy patients who may have difficulty swallowing tablets.”